These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 31550824)

  • 1. [Analysis of imatinib trough concentration at steady state in adjuvant therapy of patients with high risk gastrointestinal stromal tumor].
    Wan WZ; Zhang P; Zeng XY; Zhou H; Lin Y; Xiong Z; Zhang RZ; Liu WZ; Han Y; Tao KX
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):848-855. PubMed ID: 31550824
    [No Abstract]   [Full Text] [Related]  

  • 2. [Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients].
    Yang LX; Wang M; Xu RH; Tu L; Zhuang C; Zhao WY; Ma XL; Li M; Zhang J; Cao H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):841-847. PubMed ID: 31550823
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
    Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
    [No Abstract]   [Full Text] [Related]  

  • 4. [Changes of diagnosis and treatment for gastrointestinal stromal tumors during a 18-year period in four medical centers of China].
    Qiu H; Zhang P; Feng X; Chen T; Sun X; Yu J; Chen Z; Li Y; Tao K; Li G; Zhou Z
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1265-1270. PubMed ID: 27928797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of total and unbound imatinib and metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients.
    Streit F; Binder L; Hafke A; Brandhorst G; Braulke F; Haase D; Armbrust T; Cameron S; Ramadori G; Oellerich M; Walson P
    Ther Drug Monit; 2011 Oct; 33(5):632-43. PubMed ID: 21912334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
    Joensuu H; Wardelmann E; Sihto H; Eriksson M; Sundby Hall K; Reichardt A; Hartmann JT; Pink D; Cameron S; Hohenberger P; Al-Batran SE; Schlemmer M; Bauer S; Nilsson B; Kallio R; Junnila J; Vehtari A; Reichardt P
    JAMA Oncol; 2017 May; 3(5):602-609. PubMed ID: 28334365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A Chinese multi-center study on the significance of monitoring imatinib plasma concentration in patients with gastrointestinal stromal tumor before and after administration].
    Xu H; Ma L; Xu W; Guan W; Wang B; Li G; Miao Y; Li L; Chen H; Yu J; Wang Y; Sun L; Yang L; Zhang D; Li F; Zhi X; Wang J; Xu J; Xu Z
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1271-1276. PubMed ID: 27928798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].
    Dong Z; Gao J; Gong J; Li J; Li Y; Wang X; Li Y; Shen L; Li J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1286-1289. PubMed ID: 27928801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice.
    Rutkowski P; Ziętek M; Cybulska-Stopa B; Streb J; Głuszek S; Jankowski M; Łopacka-Szatan K; Las-Jankowska M; Hudziec P; Klimczak A; Olesiński T; Świtaj T; Koseła-Paterczyk H; Bylina E; Osuch C
    Eur J Surg Oncol; 2021 May; 47(5):1191-1195. PubMed ID: 32826113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of biological characteristics and prognosis on gastrointestinal stromal tumor with PDGFRA gene mutation].
    Qi C; Pan F; Li J; Li Y; Gao J; Shen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1280-1284. PubMed ID: 30506540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up.
    Lin JX; Chen QF; Zheng CH; Li P; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu RH; Huang CM
    J Cancer Res Clin Oncol; 2017 Apr; 143(4):727-734. PubMed ID: 28083710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinicopathological features and prognosis of gastrointestinal stromal tumor with PDGFRA-D842V mutation].
    Li XQ; Tu L; Wang M; Ma XL; Yang LX; Shen YY; Zhuang C; Zhao WY; Qiu JF; Zhao G; Cao H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):872-879. PubMed ID: 32927512
    [No Abstract]   [Full Text] [Related]  

  • 13. Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs).
    Rutkowski P; Nowecki ZI; Debiec-Rychter M; Grzesiakowska U; Michej W; Woźniak A; Siedlecki JA; Limon J; vel Dobosz AJ; Kakol M; Osuch C; Ruka W
    J Cancer Res Clin Oncol; 2007 Sep; 133(9):589-97. PubMed ID: 17458563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
    Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
    JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The outcome of targeted therapy in advanced gastrointestinal stromal tumors (GIST) with non-exon 11 KIT mutations.
    Osuch C; Rutkowski P; Brzuszkiewicz K; Bylina E; Limon J; Siedlecki JA
    Pol Przegl Chir; 2014 Jul; 86(7):325-32. PubMed ID: 25222580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical characteristics and prognosis analysis of 119 cases with giant gastrointestinal stromal tumor].
    Zhang P; Zeng X; Gao J; Liu W; Shuai X; Liu K; Liu X; Cai M; Cai K; Wang G; Tao K
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1290-1295. PubMed ID: 27928802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Significance of circulating tumor cell monitoring in targeted therapy for gastrointestinal stromal tumors].
    Fan JB; Zhi XF; Chen SS; Zhu JW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):789-795. PubMed ID: 34530560
    [No Abstract]   [Full Text] [Related]  

  • 18. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A model to predict the recurrence of middle-high risk gastrointestinal stromal tumors based on preoperative fibrinogen and peripheral blood inflammatory indexes].
    Li W; Peng QW; Lin Y; Wan WZ; Zeng XY; Sun X; Yang WC; Xiong Z; Liu WZ; Tao KX; Zhang P
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):896-903. PubMed ID: 32927515
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinicopathological features and prognostic factors of gastric intermediate-risk gastrointestinal stromal tumor after surgical resection: a retrospective study].
    Yuan W; Huang W; Ren L; Liang HY; Du XY; Fu M; Xu C; Fang Y; Shen KT; Hou YY
    Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):384-389. PubMed ID: 36973200
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 32.